History

Venatorx Pharmaceuticals was founded in June 2010 by our three visionary, fearless leaders Drs. Christopher J. Burns, Daniel C. Pevear and Luigi Xerri. Fast forward to today, we have 80+ employees, three programs discovered in-house that are now clinical stage, with more in the pipeline!! Cheers to the many milestones to come as we work purposefully every day to get antibiotics and antiviral therapies into the hands of physicians to effectively treat patients. Below just a few of the highlights!

2022

Raised Series C Financing

Announced Positive Results for Phase 3 CERTAIN-1 cUTI Study for
Cefepime-Taniborbactam

2021

Expanded Anti-Infectives Portfolio with HBV Candidate Hepatitis B Virus

Named ‘Best Places to Work’ Fourth Year in a Row

2020

Awarded NIH/NIAID Contract

Named ‘Best Places to Work’ Third Year in a Row

Partnered with GARDP

2019

Initiated Phase 3 Trial for Cefepime-Taniborbactam

Named ‘Best Places to Work’ Second Year in a Row

Announced Collaboration with BARDA (ASPR) and DTRA

Founders Named EY ‘Entrepreneurs of the Year’

President and CEO Named LSPA ‘CEO of the Year’

2018

Entered Exclusive License Agreement with Everest Medicines II Limited

Named Best Places to Work

Received Award from DTRA

Received FDA’s QIDP/Fast Track Designation for Taniborbactam (VNRX-5133)

2017

Received Funding from CARB-X

Raised $42M Series B Financing

2014

Awarded NIH R01 Grant

2013

Completed $3.5M Series A Financing

Awarded Funding from The Wellcome Trust

Awarded NIH Contract

2011

Awarded Phase 1 SBIR Grant

2010

Awarded NIH R01 Grant

Founded by Drs. Burns, Pevear and Xerri